Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors

New treatments for diabetes are always exciting in the beginning but as experience grows their position in management becomes less certain. This review focuses on DPP4 inhibitors and their place in management of type 2 diabetes. Although hypoglycaemia is rarely an issue, the effectiveness in reduction in blood sugar is greatest at the higher blood sugar levels, hence much of the value of using DPP4 inhibitors rests in the target HbA1c chosen for the individual patient. *Corresponding author: Gerald H Tomkin, Department of Diabetes and Endocrinology, Beacon Hospital and Department of Medicine, Trinity College Dublin, Ireland, Tel. +00 3531 2390658; Fax : +00 3531 2721395; E-mail: [email protected] Received December 17, 2013; Accepted January 24, 2014; Published January 31, 2014 Citation: Tomkin GH (2014) Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors. Pharmaceut Reg Affairs 3: 114. doi:10.4172/2167-7689.1000114 Copyright: © 2014 Tomkin GH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.